Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS906 in Paroxysmal Nocturnal Hemoglobinuria
NCT05889299Phase 1Completed
- Sponsor
- Omeros Corporation
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Omeros Corporation. Primary endpoint: Overall Safety and Tolerability of Zaltenibart (OMS906) Administration at 48 weeks. Started Dec 2022; status: completed.
02
Drugs
zaltenibart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05889299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889299.